Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia

Abstract

Background Antiretroviral treatment has played a pivotal role in the reduction of HIV/AIDS-related morbidity and mortality. However, treatment options can be impaired by the development of antiretroviral treatment failure. Regular monitoring of the Human Immunodeficiency Virus treatment outcome via viral load tests is the key approach. There is a scarcity of information about HIV treatment failure and risk factors in the study area. Therefore, the study was aimed to assess antiretroviral treatment failure and associated factors among patients on first-line antiretroviral treatment at Tefera Hailu Memorial Hospital, Sekota, northeast Ethiopia. Methods A hospital-based cross-sectional study was conducted on 295 patients on first-line antiretroviral treatment from Nov. 2018 to Apr. 2019. Socio-demographic and clinical variables were collected using a pretested questionnaire, and blood specimen was collected for PCR viral load and CD4 + cell count estimation. Data were entered into Epi-Info and exported to SPSS for analysis. A binary logistic regression model was used to identify associated factors, and P value < 0.05 was considered as statistically significant. Results Of the 295 subjects on first-line ART, 49 (16.6%) and 18 (6.1%) experienced virological and immunological failures, respectively. The failure of the former was associated with poor adherence (AOR: 6.367, P < 0.001), CD4 + count < 500 cells/µL (AOR: 4.78, P = 0.031) and shorter (6–24 months) duration on ART (AOR: 0.48, P = 0.048), while poor treatment adherence (AOR: 11.51, P = 0.012) and drug interruption (AOR: 6.374, P = 0.039) were the independent risk factors for latter. Immunological tests to predict virological failures showed as sensitivity, specificity, PPV, and NPV were 20.4%, 96.7%, 55.5%, and 86.0%, respectively. Conclusions The rate of ART failure was considerably high. Poor adherence, low CD4 + count, prolonged ART, and drug interruption were found to be the most predictor variables for virological and immunological failures. The discrimination power of the immunological parameter was low in comparison to virological measurements as standard methods. Therefore, the study highlighted the need for more attention and efforts to curb associated factors and maximize virological tests for monitoring treatment failures.

Time to develop severe acute malnutrition and its predictors among children living with HIV in the era of test and treat strategies at South Gondar hospitals, northwest, Ethiopia, 2021: a multicentre retrospective cohort study

“…Besides, antiretroviral therapy can prevent HIV from progressing, especially when a person starts taking it early. However, if the patients have treatment failure, HIV progressively kills the cells like CD4 T cells that help protect the body from infection, leading to complications [33][34][35].…”

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

“…Despite this, the need for life-long daily pill-taking can present substantial challenges that can be broadly grouped into three categories: adherence issues [4]; emotional issues, including stigmatization concerns and the daily reminder of HIV status [5]; and medical issues, such as difficulty swallowing, drug-food and drug-drug interactions, and pill burden [6]. These challenges can impact the likelihood of treatment failure, with poor adherence to antiretroviral therapy linked to the emergence of resistance and virologic failure [7][8][9][10]. Consequently, there is considerable interest across a range of patient demographics in long-acting therapies, in particular, injectable long-acting therapies, which may help to alleviate some of the challenges associated with daily oral therapy [11][12][13][14][15].…”

“…Increased patient satisfaction has been shown to improve adherence [23], which contributes to the maintenance of long-term HIV suppression as well as preventing drug resistance, slowing disease progression, and reducing mortality [9,10,[24][25][26]. PROs can aid treatment optimization as they provide key insights into quality-of-life issues that have the potential to influence adherence to life-long treatment.…”

Estimation of lifetime survival and predictors of mortality among TB with HIV co-infected children after test and treat strategies launched in Northwest, Ethiopia, 2021; a multicentre historical follow-up study

“…Since taking HIV medicines as prescribed can help keep the viral suppression and your CD4 cell count high [ 33 , 34 ]. Moreover, treatment failure worsens the risk of mortality of the patient as a result of ARV combination and treatment duration, which implies the antiretroviral drugs are no longer able to suppress the virus or prevent the deterioration of your immune system [ 35 , 36 ].…”